Abstract
Investigators at Massachusetts General Hospital, Boston, MA, performed a multicenter, 9-week, double-blind, placebo-controlled, dose-optimization study of guanfacine extended release (GXR, <4 mg/d) adjunctive to a long-acting psychostimulant for ADHD continued in 461 subjects.
Highlights
Investigators at Massachusetts General Hospital, Boston, MA, performed a multicenter, 9-week, double-blind, placebo-controlled, dose-optimization study of guanfacine extended release (GXR,
GXR treatment groups showed significantly greater improvement from baseline compared with placebo plus psychostimulant
Small mean decreases in pulse, systolic, and diastolic blood pressure were observed in GXR treatment groups
Summary
Investigators at Massachusetts General Hospital, Boston, MA, performed a multicenter, 9-week, double-blind, placebo-controlled, dose-optimization study of guanfacine extended release (GXR,
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
